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Key Points
• Long-term analysis of the
COMFORT-II Trial shows
that ruxolitinib treatment
results in durable reductions
in splenomegaly and is well
tolerated.
• Patients randomized to
ruxolitinib showed longer
overall survival than those
receiving the BAT.
Ruxolitinib is a potent Janus kinase (JAK)1/JAK2 inhibitor that has demonstrated rapid
reductions in splenomegaly and marked improvement in disease-related symptoms and
quality of life in patients with myelofibrosis (MF). The present analysis reports the 3-year
follow-up (median, 151 weeks) of the efficacy and safety of Controlled Myelofibrosis
Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II (the COMFORT-II
Trial), comparing ruxolitinib with the best available therapy (BAT) in 219 patients with
intermediate-2 and high-risk MF. In the ruxolitinib arm, with continued therapy, spleen
volume reductions of ‡35% by magnetic resonance imaging (equivalent to approxi-
mately 50% reduction by palpation) were sustained for at least 144 weeks, with the
probability of 50% (95% confidence interval [CI], 36-63) among patients achieving such
degree of response. At the time of this analysis, 45% of the patients randomized to
ruxolitinib remained on treatment. Ruxolitinib continues to be well tolerated. Anemia
and thrombocytopenia were the main toxicities, but they were generally manageable,
improved over time, and rarely led to treatment discontinuation (1% and 3.6% of patients,
respectively). No single nonhematologic adverse event led to definitive ruxolitinib discontinuation in more than 1 patient. Additionally,
patients randomized to ruxolitinib showed longer overall survival than those randomized to BAT (hazard ratio, 0.48; 95% CI, 0.28-0.85;
log-rank test, P 5 .009). This trial was registered at clinicaltrials.gov as #NCT00934544. (Blood. 2013;122(25):4047-4053)
Introduction
Myelofibrosis (MF) is a myeloproliferative neoplasm that can
appear de novo (primary MF) or follow polycythemia vera (PV) or
essential thrombocythemia.1 MF is characterized by bone marrow
fibrosis, extramedullary hematopoiesis with progressive splenomegaly,
cytopenias or cytosis, and a leukoerythroblastic blood picture.2,3
Main symptoms include those derived from anemia, splenomegaly
(eg, abdominal pain, early satiety), and debilitating constitutional
symptoms (ie, night sweats, weight loss, and fever) leading to
cachexia.3,4 Approximately 60% of patients with MF harbor the
V617F mutation of the Janus kinase (JAK) 2 (JAK2) gene. However,
dysregulation of the JAK/signal transducer and activator of tran-
scription pathway is present in all patients irrespective of their
JAK2 mutational status.5 Ruxolitinib is a potent JAK1/JAK2
inhibitor6 that has demonstrated rapid reductions in splenomegaly
and improved MF-related symptoms and quality of life in 2
phase 3 studies comparing ruxolitinib with placebo in the
Controlled Myelofibrosis Study With Oral JAK Inhibitor Treat-
ment (the COMFORT-I Trial)7 or best available therapy (BAT)
in the Controlled Myelofibrosis Study With Oral JAK Inhibitor
Treatment-II (the COMFORT-II Trial).8 Based on the results of
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these studies, ruxolitinib was approved by the US Food and Drug
Administration for the treatment of intermediate- or high-risk
MF and by the European Commission and Health Canada for
the treatment of disease-related splenomegaly or symptoms in
adult patients with MF. In addition to profound symptomatic
improvement, the 2-year follow-up analysis of the COMFORT-I
Trial showed a survival advantage for patients receiving ruxolitinib
as compared with placebo.7
The present analysis updates the efficacy and safety findings of
the COMFORT-II Trial with 3 years of follow-up and shows
a relative reduction in the risk of death with ruxolitinib treatment
compared with the BAT.
Methods
Study design
The COMFORT-II Trial is an open-label phase 3 study that includes
patients with a diagnosis of primary MF (PMF), post-polycythemia vera
MF (PPV-MF), or postessential thrombocythemia MF (PET-MF) by World
Health Organization and International Working Group for Myelofibrosis
Research and Treatment criteria9,10 classified as intermediate-2 or high
risk using the International Prognostic Scoring System (IPSS).3 Patients
(n 5 219) were randomized 2:1 to receive ruxolitinib (15 or 20 mg twice
daily, based on baseline platelet count [100-200 or .200 3 109/L,
respectively]) or the BAT. The latter was at the discretion of the treating
investigator, who could include any commercially available agents alone or
in combination, or no active therapy, and this could be changed at any time
during the treatment phase. Patients who progressed (defined as the need
for splenectomy or progressive splenomegaly [.25% increase in spleen
volume above the on-study nadir, including baseline]) were able to receive
ruxolitinib in an extension phase. After the primary analysis in January
2011, the study protocol was amended (amendment 5) to allow all patients
to enter the extension phase, including those who did not meet the
criteria for progression. Further details of the study design and inclusion
and exclusion criteria were previously described.8 The data cutoff for
this analysis was December 1, 2012.
The study was designed by Incyte Corporation, approved by the insti-
tutional review boards of the respective institutions, and conducted in
accordance with the principles of the Declaration of Helsinki. All patients
had provided written informed consent. Data were analyzed and interpreted
by the sponsor’s clinical and statistical teams in collaboration with the
investigators. An independent data and safety monitoring board reviewed
the trial data and made recommendations regarding the continuation of
the study.
Efficacy analyses
The primary and key secondary endpoints of the study were the proportion
of patients achieving aR35% reduction in spleen volume from baseline at
week 48 and at week 24, respectively; assessments of spleen volume by
magnetic resonance imaging were collected every 12 or 24 weeks after
week 48, depending on spleen response status. Additional secondary end
points included overall survival and the duration of spleen response. A loss
of spleen response was defined as an increase in spleen volume that was no
longer a R35% reduction from baseline and is .25% above the on-study
nadir. Assessments of symptoms and quality of life were not collected
beyond week 48 or for patients who entered the extension phase.
Efficacy results are based on an intention-to-treat analysis. For the as-
sessment of spleen response, results are shown for the randomized and
extension phases for both the ruxolitinib and the BAT arms and include
patients who crossed over from BAT to ruxolitinib. For assessment of the
duration of spleen response, data from the randomized and extension phases
are shown for ruxolitinib-treated patients and until crossover for BAT-
treated patients.
Measurement of the dynamics of JAK2 V617F allele burden in patients
with the mutation was an exploratory end point. JAK2 V617F allele burden
was measured from blood samples using allele-specific quantitative real-
time polymerase chain reaction, as described in 2006 by Levine et al,11
using an Applied Biosystems ABI 7900 real-time polymerase chain reaction
(PCR) analyzer.
Overall survival was estimated using the Kaplan-Meier method, and the
hazard ratio was determined using the Cox proportional hazards model
stratified by baseline IPSS category. The P value was determined by using
the stratified log-rank test and was presented at face value without adjustment
for multiple comparisons.
Safety
Safety results are summarized for the entire duration of treatment of patients
randomized to ruxolitinib (ie, randomized and extension phases) for the
duration of BAT until crossover for patients randomized to BAT (ie,
randomized phase only), and separately after crossover for BAT patients
who received ruxolitinib treatment in the extension phase. Nonhematologic
adverse events (AEs) are summarized by adjusted rate per 100 patient-year
exposure. AEs of special interest were defined by previously known or
potential toxicities and are presented as the incidence rate by 24-week
intervals.
Results
Patients
The patient details and primary results of the study were previously
reported, with shorter treatment duration (median, 50.1 weeks).8 In
brief, baseline characteristics were well-balanced between treat-
ment groups; 53% of patients had PMF, 31% PPV-MF, and 16%
PET-MF. Approximately 40% and 60% of patients in both arms
were clinically confirmed as intermediate-2 or high risk, respec-
tively, according to the IPSS.3
Overall, 73% of patients (106 of 146) in the ruxolitinib arm and
62% (45 of 73) in the BAT arm entered the extension phase to
receive ruxolitinib, and at the time of this analysis, 45% (66 of 146)
of those originally randomized to ruxolitinib remained on treatment
(Table 1). The median follow-up was 151 weeks (ruxolitinib, 151
weeks; BAT, 122 weeks), and the median duration of exposure
was 136 weeks to ruxolitinib (randomized and extension phases)
and 45 weeks to BAT (randomized treatment only). For patients
starting on 20 mg twice daily, the median ruxolitinib daily dose
remained stable to week 48 (39.7 mg/day) and then decreased
slightly over time to week 144 (34.3 mg/day). In the 15 mg twice daily
group, the median dose intensity decreased over the first 24 weeks
of therapy and stabilized at approximately 20 mg/day (20.8 mg/day
at week 144; supplemental Figure 1; available on the BloodWeb site).
In the BAT arm, 24 patients (33%) received no active treatment while
on the study; of the 67% of patients who received the BAT, the most
commonly used therapies were antineoplastic agents (51%), primarily
hydroxyurea (n 5 34), and glucocorticoids (16%). Of the patients
who crossed over from the BAT arm to receive ruxolitinib, 42%
(19 of 45) did not receive MF-specific medication, and 58% (26 of
45) were on active treatment (with 18 who received hydroxyurea).
Efficacy
Spleen response. In the ruxolitinib arm, 97% of patients (132 of
136) with post-baseline assessments experienced a clinical benefit
with some degree of reduction in spleen volume at any time of the
study, and 51% (75 of 146) achieved a protocol-defined spleen
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response of a R35% spleen reduction. Six patients achieved the
spleen response after the primary analysis at week 48 and are
included in this analysis. BAT patients who crossed over to
ruxolitinib had reductions in spleen volume after crossover (Figure 1).
One patient in the BAT arm achieved a R35% reduction in spleen
volume at week 15 but did not maintain the response at week 48.
This patient crossed over to the ruxolitinib arm without having
a protocol-defined progression event and was excluded from the
per-protocol analysis. The spleen reductions ofR35% obtained with
ruxolitinib were sustained with continued therapy (median duration
not yet reached; Figure 2). The Kaplan-Meier estimated probabilities
of maintaining the spleen response at weeks 48 and 144 were
73% (95% CI, 61-82) and 50% (95% CI, 36-63), respectively.
JAK2 V617F allele burden. At baseline, 110 patients (76%)
in the ruxolitinib arm and 49 patients (71%) in the BAT arm were
determined to be JAK2 V617F-positive, and the median allele
burdens were 84.5% (range, 5% to 96%) and 81% (range, 1% to
95%) in the ruxolitinib and BAT arms, respectively. Overall,
patients in the ruxolitinib arm had a median change from baseline
of 27.0% at week 48 (range, 247% to 8%; n 5 69) and 28.0% at
week 72 (range,251% to 15%; n5 53), whereas those in the BAT
arm had no median change from baseline at either time point (week
48: range, 213% to 10%; n 5 22) (week 72: range, 24% to 12%;
n 5 8). More patients in the ruxolitinib arm had allele burden
reductions ofR10% compared with BAT patients at week 48 (42%
[29 of 69] vs 9% [2 of 22]) and at week 72 (40% [21 of 53] vs 0%).
Of these, 15 of 69 ruxolitinib-treated patients (22%) had reductions
of R20% at week 48 (median, 232%; range, 247% to 221%),
and 83% of patients maintained their reduction at the last time
point of week 72 (median, 240%; range, 251% to 220%). Allele
burden reductions in most patients treated with ruxolitinib were
gradual over the course of the study, and were similar across MF
subtypes (supplemental Figure 2). Among patients who achieved
R20% of a reduction in allele burden, 39% had PMF, 39% had
PPV-MF, and 22% had PET-MF, similar to the overall study
population. No patient receiving the BAT had allele burden reduc-
tions ofR20% at either time point. Additionally, a higher propor-
tion of patients with R20% of an allele burden reduction achieved
a protocol-defined spleen response with ruxolitinib compared with
those with ,10% of a reduction at both week 48 (73% vs 19%;
odds ratio, 4.6) and week 72 (69% vs 22%; odds ratio, 4.2)
(supplemental Figure 3).
Safety
Nonhematologic toxicity was primarily grade 1/2, and the overall
pattern and frequency of the most common AEs (ie, observed in
R10% of patients) did not change with longer treatment. When
adjusted for exposure to study medication (Table 2), the rates of
nonhematologic AEs generally decreased with longer-term rux-
olitinib treatment and were lower than in the BAT. Additionally,
no single nonhematologic AE led to treatment discontinuation in
more than 1 patient.
The AEs of special interest included anemia, thrombocytopenia,
leukopenia, bleeding, infections, thromboembolic events, elevated
transaminase levels, increased systolic blood pressure, weight gain,
and secondary malignancies. All grade AEs of special interest that
occurred in R5% of patients in any interval and in any preferred
term are shown by 6-month intervals in Table 3. The rate of these
events generally decreased with longer exposure to ruxolitinib
treatment, with the highest rates occurring within the first 6 months
of treatment. Over the entire course of the study, 2 patients (1.4%)
in the ruxolitinib arm had tuberculosis.
New or worsening AEs that occurred within 28 days after
ruxolitinib discontinuation were also recorded (supplemental Table 1).
The rate and severity of these AEs did not differ from what was
reported for AEs occurring for patients on treatment, or they were
consistent with those expected for patients receiving no treatment.
Overall, 30.1% of patients (31 of 103) reported experiencing AEs
after discontinuation of ruxolitinib treatment (including after cross-
over from BAT), and the most common were infections (13.6%
[14 of 103]) and thrombocytopenia (9.7% [10 of 103]). The
majority of safety events occurred in only 1 patient each; events
occurring after discontinuation in .1 patient in either the ruxolitinib
arm or after crossover from the BAT included preferred terms of
thrombocytopenia (n 5 10), pneumonia (n 5 3), anemia (n 5 2),
and hypoalbuminemia (n 5 2).
The most common laboratory abnormalities were anemia and
thrombocytopenia. However, the majority of these AEs were grade
Table 1. Patient disposition at 3-year follow-up of the COMFORT-II Trial
n (%)
Ruxolitinib
(n 5 146)
BAT
(n 5 73)
Ruxolitinib
after
BAT (n 5 45)
Still on treatment 66 (45.2) 0 —
Discontinued 80 (54.8) 28 (38.4) —
Crossed over* — 45 (61.6) —
After qualifying progression
event
— 26 (35.6) —
After protocol amendment 5 — 13 (17.8) —
Other† — 6 (8.2) —
Still on treatment after crossover — — 22 (48.9)
Discontinued after crossover — — 23 (51.1)
Primary reasons for
discontinuation
AE 24 (16.4) 5 (6.8) 6 (13.3)
Consent withdrawn 9 (6.2) 9 (12.3) 0
Protocol deviation 2 (1.4) 0 5 (11.1)
Disease progression 22 (15.1) 4 (5.5) 6 (13.3)
Noncompliance with study
medication
3 (2.1) 0 1 (2.2)
Noncompliance with study
procedures
0 1 (1.4) 0
Unsatisfactory therapeutic
effect
5 (3.4) 0 1 (2.2)
Other‡ 15 (10.3) 9 (12.3) 4 (8.9)
*Patients randomized to the BAT arm could crossover to ruxolitinib treatment at
any time during the study upon a protocol-defined progression event. Patients in the
ruxolitinib arm who had a protocol-defined progression event could continue
receiving ruxolitinib in the extension phase at any time during the study if, in the
investigator’s opinion, they were still receiving a benefit from ruxolitinib treatment.
Progression events that qualified for the crossover and extension phases included
the need for splenectomy and progressive splenomegaly as defined by a 25%
increase in spleen volume compared with the on-study nadir (including baseline).
After the primary analysis, the study protocol was amended (amendment 5) in
January 2011 to allow all patients to enter the extension phase, including those who
did not meet the criteria for progression.
†Six patients crossed over from BAT to ruxolitinib prior to protocol amendment 5
without experiencing qualifying progression events (5 patients discontinued due to
the protocol deviation and 1 patient discontinued due to other reason).
‡Other reasons for discontinuation in the ruxolitinib arm included patients who
underwent stem cell transplant (n5 5), interruption of study medication for.8 weeks
(n 5 2), lack of efficacy (n 5 2), meeting protocol-defined imaging discontinuation
criteria (n 5 2), investigator decision (n 5 1), diagnosis of lung cancer with the start
of chemotherapy treatment (n 5 1), unspecified safety event (n 5 1), and modest
spleen response (n5 1). Other reasons in the BAT arm included stem cell transplant
(n5 2), investigator decision (n5 2), patient decision (n5 2), splenic irradiation (n5 1),
hematemesis and thrombocytopenia (n 5 1), unwillingness to undergo magnetic
resonance imaging (n 5 1), enrollment in a ruxolitinib compassionate use program
(n 5 1), splenectomy (n 5 1), initiating treatment with hydroxyurea (n 5 1), and
thrombocytopenia as sign of disease progression (n 5 1).
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1/2 (supplemental Table 2) and rarely led to treatment discontinu-
ation among patients who received ruxolitinib, including extension
phase and crossover from BAT. Thus, only 2 patients (1%) discon-
tinued the treatment due to anemia or hemoglobin decreases and 7
(3.6%) due to thrombocytopenia or platelet count decreases. In the
ruxolitinib arm, mean hemoglobin levels decreased over the first 12
weeks of treatment and then recovered to levels similar to those in
the BAT patients and remained .10 g/dL from week 24 onward
(Figure 3). Similarly, the transfusion rate was slightly higher in the
ruxolitinib arm over the first 24 weeks, but declined thereafter to
a rate similar to that in the BAT arm (supplemental Figure 4).
During treatment or within 28 days after discontinuation of
study medication, there were 13 deaths (8.9%) in the ruxolitinib
arm, 4 deaths (5.5%) in the BAT arm during randomized treatment,
and 1 (2.2%) after crossover from BAT at the time of data cutoff. A
patient can have multiple causes of death and be included in R1
category; in the ruxolitinib arm, each cause of death category
included only 1 patient. Causes of death in the ruxolitinib arm during
randomized treatment included cardiac arrest, cardiac failure,
intestinal perforation, retroperitoneal hemorrhage, disease pro-
gression, multiorgan failure, hepatic failure, portal vein thrombosis,
endocarditis, septic shock, postoperative respiratory distress, and
cerebral hemorrhage (1 patient each). Causes of death during
ruxolitinib treatment in the extension phase included enterococcal
sepsis, febrile infection, pneumonia, cerebrovascular accident, and
depressed level of consciousness (1 patient each). Causes of death
in the BAT arm during randomized treatment included respiratory
failure (n 5 2), cardiac failure (n 5 1), and renal impairment
(n 5 1); causes of death after crossover from BAT to ruxolitinib
included ascites and Klebsiella sepsis (both in the same patient).
At the time of the primary analysis at 48 weeks, 2 cases of
transformation to acute leukemia (defined as a peripheral blood
blast count ofR20% sustained forR 8weeks or a bone marrow
blast count of R20%) were reported in BAT-treated patients.8
With this longer follow-up, 5 patients (3.4%) in the ruxolitinib
arm and 4 patients (5.5%) in the BAT arm experienced leukemic
transformation (1 of which was recorded in the safety database as
a serious AE).
Overall survival analysis
Since the last report (median, 112 weeks),12 an additional 9 and 6
deaths were reported overall in the ruxolitinib and BAT arms,
resulting in a mortality rate of 19.9% (29 of 146) and 30.1% (22 of
73) of patients, respectively; therefore, the median survival time
has not yet been reached in either arm (Figure 4). Among the
patients who died in the BAT arm (22 in total), only 4 patients did
not receive any MF-specific medication, and 18 had active treatment
(patients may have receivedR1 BAT medications at any given time).
Patients randomized to ruxolitinib showed longer overall survival
than those randomized to BAT; there was a 52% reduction in the
risk of death in the ruxolitinib arm compared with the BAT arm
Figure 1. Mean percentage change in spleen volume
over time. Assessments of changes in spleen volume
in the BAT arm were determined based on the patients’
original baseline spleen volume and not from the time
of crossover. Patients crossed over from the BAT arm
to receive ruxolitinib over the course of approximately
6 to 8 months.
Figure 2. Duration of spleen response. Includes
randomized and extension phases for patients ran-
domized to ruxolitinib; crossover patients are not in-
cluded. Duration of maintenance was estimated only
for patients who achieved a $35% reduction in
spleen volume. The start date was defined as the
first spleen volume measurement that was a $35%
reduction from baseline (minimum of 12 weeks [ie,
first on-treatment assessment by magnetic reso-
nance imaging]), and the end date was the first
measurement that was no longer a $35% reduction
and that was a .25% increase above the nadir.
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(hazards ratio, 0.48; 95% CI, 0.28-0.85; P 5 .009). The Kaplan-
Meier estimated probability of survival at 144 weeks was 81% in
the ruxolitinib arm and 61% in the BAT arm.
Discussion
This longer follow-up of the COMFORT-II Trial shows that the
reductions in the spleen volume observed at the time of the initial
analysis in the patients assigned to the ruxolitinib arm were
maintained with continued treatment in a substantial proportion of
the patients. Thus, the median duration of a spleen response has not
yet been reached after 3 years, although only a few more events are
required. In this sense, it must be noted that the patients in this
analysis were in the advanced stages of MF (intermediate-2 and
high-risk groups), as required for inclusion in this study.
As expected, and given its mechanism of action as a JAK1 and
JAK2 inhibitor, the most common AEs associated with ruxolitinib
were anemia and thrombocytopenia. However, most events were
grade 1/2 and rarely led to definitive treatment discontinuation.
Thus, among patients receiving ruxolitinib, including the extension
phase and crossover from BAT, only 2 patients discontinued due to
anemia and 7 due to thrombocytopenia. In addition, mean hemoglobin
levels in the ruxolitinib arm decreased at the beginning of treatment
and recovered to levels similar to those of the BAT patients from
week 24 onward, whereas the transfusion rate was slightly higher
in the ruxolitinib arm over the first 24 weeks and declined thereafter
to a rate similar to that in the BAT arm. Concerning nonhematologic
toxicity, an increased frequency of infections was observed under
ruxolitinib. However, these complications were rarely severe and
tended to decrease over time. Overall, no new safety signals have
emerged with this longer-term ruxolitinib treatment compared
with the initial analysis.
The survival advantage with ruxolitinib treatment compared
with BAT in this update confirms the results obtained in a previous
analysis performed after a median follow-up of 112 weeks.12 This
advantage is noteworthy, taking into account the expected survival
of the patient population included in the study. Indeed, the
expected median survival for patients with intermediate-2 risk
MF (ie, 60% of the patients in the study) is 48 months and 27
months for patients with high-risk MF.3 Therefore, given the
composition of the study population, the expected median
survival would have slightly exceeded the 3 years of the current
follow-up. In this sense, a difference in survival between the 2
arms may not have been observed at earlier time points for several
reasons. First, as mentioned before, the MF population included
in the study had an expected median survival that is less than
the median duration of follow-up for most patients, and therefore,
the death events were expected to occur not at the beginning
of the study but later. Second, the 2:1 randomization means there
are fewer potential events in the comparator arm. In addition,
a considerable number of patients in the BAT arm were censored
prior to 48 weeks (24.7% of patients in the BAT arm and 9.6% of
patients in the ruxolitinib arm).12 Most patients in the BAT arm
Table 2. Nonhematologic AEs regardless of study drug
Adjusted
rate per 100
patient-year
exposure
Ruxolitinib
randomized
(n 5 146)
Ruxolitinib
randomized
1
extension
(n 5 146)
BAT
randomized
(n 5 73)
Ruxolitinib
crossover
(n 5 45)
Patient-year
exposure
170.12 304.87 66.98 44.95
Peripheral edema 20.0 (0) 17.4 (0) 31.4 (1.5) 17.8 (2.2)
Diarrhea 22.3 (1.2) 15.4 (0.7) 19.4 (0) 20.0 (0)
Asthenia 16.5 (2.4) 11.5 (1.6) 13.4 (1.5) 17.8 (2.2)
Dyspnea 14.1 (1.2) 11.2 (1.3) 22.4 (4.5) 20.0 (2.2)
Pyrexia 12.9 (1.8) 11.5 (1.3) 10.5 (0) 13.3 (0)
Fatigue 13.5 (0.6) 11.2 (0.7) 11.9 (0) 13.3 (2.2)
Nasopharyngitis 15.9 (0) 11.8 (0) 14.9 (0) 8.9 (0)
Bronchitis 10.6 (1.2) 11.5 (1.3) 9.0 (1.5) 6.7 (0)
Cough 12.9 (0) 10.5 (0) 17.9 (1.5) 11.1 (2.2)
Arthralgia 11.2 (1.2) 8.9 (0.7) 10.5 (0) 13.3 (2.2)
Weight gain 13.5 (1.8) 9.5 (1.0) 1.5 (0) 8.9 (0)
Nausea 12.3 (0.6) 8.9 (0.3) 10.5 (0) 8.9 (0)
Pain in extremity 10.0 (0.6) 7.2 (0.3) 6.0 (0) 20.0 (0)
Headache 10.6 (1.2) 6.9 (0.7) 6.0 (0) 15.6 (0)
Back pain 10.6 (1.8) 7.5 (1.3) 14.9 (0) 6.7 (0)
Insomnia 5.3 (0) 3.9 (0) 10.5 (0) 8.9 (0)
Abdominal pain 10.0 (2.9) 6.6 (1.6) 19.4 (4.5) 6.7 (2.2)
Epistaxis 7.6 (0) 5.2 (0.7) 7.5 (0) 11.1 (0)
Pruritus 5.3 (0) 5.2 (0) 19.4 (0) 8.9 (0)
Data are presented as adjusted rates for all grades, with grades 3/4 given in
parentheses. Relationship adjusted for patient-year exposure (rate of $10 per
100 patient-years in either arm) by preferred term. AEs regardless of study drug
relationship occurring .28 days after discontinuation of study medication are not
summarized. A patient with multiple occurrences of an AE under 1 treatment is
counted only once in the AE category for that treatment.
Table 3. AEs of special interest by 6-month intervals
Ruxolitinib randomized 1
extension, %
Week
0-24 (n 5 146) 24-48 (n 5 134) 48-72 (n 5 116) 72-96 (n 5 101) 96-120 (n 5 93) 120-144 (n 5 81) 144-168 (n 5 72)
Anemia* 34.9 12.7 8.6 13.9 8.6 7.4 8.3
Thrombocytopenia† 43.2 22.4 15.5 12.9 10.8 12.3 2.8
Bleeding 17.1 14.2 9.5 11.9 7.5 9.9 6.9
Epistaxis 6.8 1.5 0.9 4.0 0 1.2 1.4
Hematoma 5.5 4.5 3.4 1.0 0 2.5 1.4
Infections 50.0 35.1 37.9 25.7 43.0 33.3 25.0
Bronchitis 3.4 6.7 8.6 3.0 10.8 4.9 4.2
Gastroenteritis 5.5 3.0 0.9 1.0 2.2 1.2 0
Nasopharyngitis 13.7 5.2 7.8 4.0 10.8 3.7 4.2
Urinary tract infection 4.8 2.2 5.2 4.0 5.4 3.7 2.8
Weight gain 8.2 8.2 5.2 5.0 2.2 0 0
Data are presented as the percentage of patients. All grades for $5% of patients in any preferred term within the standardized MedDRA queries (SMQ) and any interval.
Patients are counted only once in each category and time interval. AEs of special interest include anemia, thrombocytopenia, leukopenia, bleeding, infections,
thromboembolic events, weight gain, elevated transaminase levels, increased systolic blood pressure, and secondary malignancies.
*Includes preferred terms of anemia and normochromic normocytic anemia; the SMQ term is erythropenia.
†Includes preferred terms of thrombocytopenia and platelet count decreased.
BLOOD, 12 DECEMBER 2013 x VOLUME 122, NUMBER 25 LONG-TERM FINDINGS WITH RUXOLITINIB FOR MF 4051
For personal use only.on January 22, 2016. by guest  www.bloodjournal.orgFrom 
who were lost to follow-up discontinued because of consent
withdrawal, likely because of a lack of benefit from study
medication, whereas the lower proportion of patients lost to
follow-up in the ruxolitinib arm was primarily related to
intolerance and, to a lesser degree, lack of benefit from study
medication. In addition, patients were allowed to crossover from
the BAT arm to receive ruxolitinib and, in an intention-to-treat
analysis, these patients are considered to be under BAT treat-
ment. The late separation observed between the Kaplan-Meier
curves (after 72 weeks) may reflect outcome differences in-
curred within the first 48 weeks of the study, including im-
provements in splenomegaly, constitutional symptoms, MF-related
symptoms, and patients’ general condition in ruxolitinib-treated
patients, and worsening in patients receiving the BAT. De-
spite these factors, there was a relative reduction in the risk of
death with ruxolitinib treatment compared with conventional
therapies.
One of the ways that ruxolitinib may improve survival is by
ameliorating the patients’ nutritional status and general health-
related quality of life, thereby making patients less vulnerable and
increasing their ability to withstand multiple causes of mortality.
This hypothesis is supported by a post hoc analysis of survival
outcomes in the COMFORT-I Trial, in which patients who had
reductions in cachexia and larger improvements in cholesterol
Figure 3. Hemoglobin levels and platelet counts
over time. Ruxolitinib includes both the randomized
and extension phases; BAT includes the random-
ized phase only and not the assessments after crossover.
Figure 4. Kaplan-Meier analysis of overall survival
in the COMFORT-II Trial. In this intention-to-treat
analysis of overall survival, patients who crossed over
from the BAT arm to receive ruxolitinib are included in
the BAT group.
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levels had significantly longer survival than those who had lesser
improvements.13 Another potential mechanism would be the reduction
or normalization of circulating levels of inflammatory cytokines,
which are integral to MF progression and likely contribute to disease-
related symptoms.14 Additionally, a recent report by Kvasnicka
et al15 has retrospectively analyzed the fibrosis scores among
patients receiving ruxolitinib in the phase 1/2 study compared
with those in a control group of patients treated with the BAT,
showing stabilization or improvement in the fibrosis after 24 and
48 months under ruxolitinib and worsening in the fibrosis over the
same time in patients receiving the BAT. This hypothesis, however,
requires further exploration, including the analysis of the correlations
between the bone marrow changes and the evolution of the clinic-
hematologic findings reflecting the MF activity in the context of
JAK1/JAK2 inhibitor treatment.
In conclusion, ruxolitinib provided rapid and durable reductions
in splenomegaly in MF that were sustained for 3 years of treatment
in the majority of patients in the COMFORT-II Trial. Ruxolitinib
continues to be well tolerated, with nearly half of the patients re-
maining on the study. Additionally, the present results suggest a
relative reduction in the risk of death with ruxolitinib compared
with BAT, confirming the survival advantage observed in the pre-
vious update of the COMFORT-II Trial.12
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